GLOW1 and GLOW2 – Zenkuda was effective in preventing meaningful worsening in diabetic retinopathy severity 11 GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130); Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates Proportion of patients with ≥2 - and ≥3 - Step Worsening in DRSS from Baseline to Week 48 GLOW1 GLOW2 13.1% 4.6% 0% 0% 0% 5% 10% 15% 20% 25% ≥2-Step Worsening ≥3-Step Worsening Sham Zenkuda 3.9% 2.3% 0.7% 0% 0% 5% 10% 15% 20% 25% ≥2-Step Worsening ≥3-Step Worsening Sham Zenkuda Figure 8